Materialise N.V. logo

Materialise N.V.

MTLS

NASDAQTechnologySoftware - Application

Regular session

$6.57

−$0.04 · -0.61%

Aug 24, 10:19 AM ET

MTLS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

65

Undervalued

Momentum

52

Neutral

Sentiment

48

Mixed

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.

Industry
Software - Application
Sector
Technology
Headquarters
BE
CEO
Brigitte de Vet-Veithen
Listed since
Jun 25, 2014
Employees
2,556

Market position

Day range

Current $6.57

52-week range

Current $6.57

Open
$6.60
Previous close
$6.61
Volume
35.79K
0.32× average
Average volume
110.83K
Average daily volume
Market cap
384.71M USD
Beta
1.35
Market reference 1
50-day average
$6.7294
-2.37% below average
200-day average
$5.894
+11.47% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
32.13×
P/B (TTM)
1.3×
P/S (TTM)
1.23×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
57.60%
Operating margin
3.91%
Net margin
3.76%

Financial health

Debt / equity
0.24×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends63%40%16%-7%Gross margin, FY2021: 57.52%Gross margin, FY2022: 55.50%Gross margin, FY2023: 56.66%Gross margin, FY2024: 56.54%Gross margin, FY2025: 57.15%Operating margin, FY2021: 5.95%Operating margin, FY2022: -1.24%Operating margin, FY2023: 2.19%Operating margin, FY2024: 3.54%Operating margin, FY2025: 1.92%Net margin, FY2021: 6.40%Net margin, FY2022: -0.91%Net margin, FY2023: 2.62%Net margin, FY2024: 5.04%Net margin, FY2025: 2.88%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 57.52%. Gross margin FY2022 55.50%. Gross margin FY2023 56.66%. Gross margin FY2024 56.54%. Gross margin FY2025 57.15%. Operating margin FY2021 5.95%. Operating margin FY2022 -1.24%. Operating margin FY2023 2.19%. Operating margin FY2024 3.54%. Operating margin FY2025 1.92%. Net margin FY2021 6.40%. Net margin FY2022 -0.91%. Net margin FY2023 2.62%. Net margin FY2024 5.04%. Net margin FY2025 2.88%.

Income trends

Revenue

257.07M USD-3.63%

Operating income

4.94M USD-47.58%

Net income

7.41M USD-44.82%
Income trends across reported periods293.73M USD185.87M USD78.02M USD−29.84M USDRevenue, FY2021: 205.45M USDRevenue, FY2022: 232.02M USDRevenue, FY2023: 256.13M USDRevenue, FY2024: 266.77M USDRevenue, FY2025: 257.07M USDOperating income, FY2021: 12.22M USDOperating income, FY2022: −2.87M USDOperating income, FY2023: 5.62M USDOperating income, FY2024: 9.43M USDOperating income, FY2025: 4.94M USDNet income, FY2021: 13.15M USDNet income, FY2022: −2.12M USDNet income, FY2023: 6.72M USDNet income, FY2024: 13.44M USDNet income, FY2025: 7.41M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 205.45M USD. Revenue FY2022 232.02M USD. Revenue FY2023 256.13M USD. Revenue FY2024 266.77M USD. Revenue FY2025 257.07M USD. Operating income FY2021 12.22M USD. Operating income FY2022 −2.87M USD. Operating income FY2023 5.62M USD. Operating income FY2024 9.43M USD. Operating income FY2025 4.94M USD. Net income FY2021 13.15M USD. Net income FY2022 −2.12M USD. Net income FY2023 6.72M USD. Net income FY2024 13.44M USD. Net income FY2025 7.41M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue257.07M USD266.77M USD256.13M USD232.02M USD205.45M USD
Cost of goods sold110.16M USD115.94M USD111M USD103.26M USD87.28M USD
Gross profit146.91M USD150.83M USD145.13M USD128.77M USD118.17M USD
Research and development44.27M USD44.4M USD38.1M USD37.57M USD26.89M USD
Selling, general, and administrative96.32M USD101.22M USD94.89M USD93.02M USD77.59M USD
Operating expenses141.97M USD141.39M USD139.51M USD131.64M USD105.96M USD
Interest income3.81M USD4.25M USD4.45M USD1.4M USD777.74K USD
Interest expense5.39M USD1.65M USD2.09M USD2.92M USD3.36M USD
Depreciation and amortization20.85M USD21.81M USD21.57M USD22.57M USD20.55M USD
Operating income4.94M USD9.43M USD5.62M USD−2.87M USD12.22M USD
Net income7.41M USD13.44M USD6.72M USD−2.12M USD13.15M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
70%
7 beats, 2 misses, 1 met estimate
Average EPS surprise
+172.99%
10 comparable reports
Latest EPS result
0.03
Estimate 0.01 · Beat by 200.09%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.160.090.02-0.05Q1 '25MetQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26EstimateQ3 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 0.05, estimate 0.05, surprise 0.00%, Met estimate. Q2 2025, reported Apr 24, 2025: actual -0.01, estimate 0.02, surprise -150.00%, Miss. Q3 2025, reported Jul 24, 2025: actual 0.004, estimate 0.01, surprise -60.30%, Miss. Q4 2025, reported Oct 28, 2025: actual 0.04, estimate 0.01, surprise +300.00%, Beat. Q1 2026, reported Feb 19, 2026: actual 0.12, estimate 0.07, surprise +70.29%, Beat. Q2 2026, reported May 7, 2026: actual 0.035, estimate 0.012, surprise +200.09%, Beat. Q3 2026, reported Jul 23, 2026: actual —, estimate 0.046, surprise —, Comparison unavailable. Q3 2026, reported Aug 27, 2026: actual —, estimate 0.046, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates86.4M77.52M68.65M59.78MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26EstimateQ3 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 68.01M USD, estimate 63.1M USD, surprise +7.78%, Beat. Q2 2025, reported Apr 24, 2025: actual 72.77M USD, estimate 67.21M USD, surprise +8.28%, Beat. Q3 2025, reported Jul 24, 2025: actual 76.33M USD, estimate 67.28M USD, surprise +13.46%, Beat. Q4 2025, reported Oct 28, 2025: actual 77.8M USD, estimate 70.73M USD, surprise +9.99%, Beat. Q1 2026, reported Feb 19, 2026: actual 82.41M USD, estimate 83.07M USD, surprise -0.80%, Miss. Q2 2026, reported May 7, 2026: actual 76.57M USD, estimate 77.06M USD, surprise -0.64%, Miss. Q3 2026, reported Jul 23, 2026: actual —, estimate 78.23M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 27, 2026: actual —, estimate 78.23M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

12 ratings
Strong buy00%
Buy867%
Hold433%
Sell00%
Strong sell00%

MTLS news

MTLS peers

ETFs holding MTLS

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research MTLS

research.disclaimer